In Recent Guidance, FDA aims for Patient Safety at 503B Facilities
The FDA has issued a guidance to 503B facilities regarding Current Good Manufacturing Practice (gCMB)
The FDA has issued a guidance to 503B facilities regarding Current Good Manufacturing Practice (gCMB)
Just last week, ConsortiEX proudly announced our new InsightRX Passive Audit Monitoring module.
The practice of compounding medicines can provide important public health opportunities. The FDA’s compounding program – including implementation of the compounding provisions of the law – is a priority for the agency. We recognize that in delivering on implementation commitments, we must balance the need to preserve[...]
We want to thank everybody who came to visit our booth at this year’s ASHP Summer Meetings & Exhibition.
We recently sat down with ConsortiEX CEO, Neal Long, to discuss the company’s background and learn more about its plans to help hospitals safely distribute, source and track compounded pharmaceuticals among affiliated hospitals. addresses the worldwide problem of drug availability, patient safety and high costs. The[...]
Office: (414) 231-4575
Support: (888) 434-1442
2020 | ConsortiEX Inc. | All Rights Reserved